Assembly Biosciences
ASMB
118 hedge funds and large institutions have $502M invested in Assembly Biosciences in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 44 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
11% more funds holding
Funds holding: 106 → 118 (+12)
0.11% more ownership
Funds ownership: 7.64% → 7.75% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 44
28% less capital invested
Capital invested by funds: $700M → $502M (-$198M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$10.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.44M |
| 3 |
Morgan Stanley
New York
|
+$7.76M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$6.21M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$25.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.7M |
| 3 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$3.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.81M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.65M |
ASMB Hedge Fund Activity: Q3 2020 in Review
118 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2020, worth a combined $502M — down 28% from $700M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ASMB positions and 10 closed out — a net gain of 12 holders — while 32 added to existing stakes and 44 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $10.9M. The largest seller was Consonance Capital Management, cutting an estimated $25.3M.
- 118 institutional investors held Assembly Biosciences (ASMB) as of Q3 2020, up from 106 in Q2 2020.
- Funds reported $502M of Assembly Biosciences stock for Q3 2020, down 28% quarter-over-quarter.
- 22 funds opened new Assembly Biosciences positions in Q3 2020 and 10 closed out, a net change of +12 holders.
- The largest Assembly Biosciences buyer in Q3 2020 was HealthCor Management, an estimated $10.9M added.
- The largest Assembly Biosciences seller in Q3 2020 was Consonance Capital Management, an estimated $25.3M sold.
Based on aggregated 13F filings for Q3 2020.